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measure, but this has not been supported.4 Despite this,
half of patients with advanced cancer who lose 10 or
more points per week die within two weeks (95% confi›
dence interval 8.6 days to 19.4 days), and three quarters
are dead at three weeks. In contrast, 50% of patients in
whom the weekly score does not deteriorate survive for
two months (35.2 days to 76.8 days).
Although Barthel score at admission correlated
with overall survival, no differences in scores on
admission were found among the three groups in
either sample (sample 1, P = 0.08, and sample 2,
P = 0.74, Kruskal›Wallis; see table on website). Admis›
sion score therefore cannot be used to determine pat›
tern of subsequent change and hence to estimate
survival more accurately.
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Drug points
Apparent interaction between warfarin and
levonorgestrel used for emergency contraception
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Emergency contraception with progestogen only (two
doses of levonorgestrel 0.75 mg given 12 hours apart and
within 72 hours of unprotected intercourse) is better
tolerated and more effective than the combined
oestrogen›progestogen (Yuzpe) regimen.1 Furthermore,
treatment with progestogen only may be preferable to the
Yuzpe regimen in women with a known thrombophilic
defect or history of thromboembolic events. For women
receiving warfarin, drug information cites either no inter›
action between progestogens and warfarin2 or a reduction
in anticoagulant effect.3 We describe an enhanced
anticoagulant effect of warfarin after giving a woman
levonorgestrel for emergency contraception.
A 35 year old woman with familial type 1 (quantitative)
antithrombin deficiency and a history of extensive deep
venous thrombosis and pulmonary thromboembolism,
attended the clinic after an episode of unprotected
intercourse. She was receiving warfarin 7 mg daily for
anticoagulation but no other drugs. Her international
normalised ratio was 2.1, which was within the therapeutic
range (2.0›3.0). She requested emergency contraception.
After counselling, she declined the insertion of an intra›
uterine contraceptive device, preferring the progestogen
only regimen. Her international normalised ratio was
rechecked three days later and was reported as 8.1. She
was advised to discontinue warfarin treatment for two
days, at which point her international normalised ratio was
2.5, and then to restart it at a dose of 5 mg once daily. No
haemorrhagic problem occurred.
One possible explanation for this enhanced anti›
coagulant effect is the displacement of warfarin by
levonorgestrel from the F1S binding site of human á1›acid
glycoprotein, the main transport protein for drugs in
plasma.4 The variant of the F1S binding site comprises
part of the F1S/A phenotype of á1›acid glycoprotein,
which is encountered in 50% of the population.
Thus women receiving warfarin treatment may be at
risk of an interaction between warfarin and levonorgestrel if
they are prescribed the progestogen only regimen because
of its apparent safety. The manufacturer of levonorgestrel
(Wyeth) has not received any reports describing such an
interaction with warfarin. This potential interaction requires
prompt investigation, particularly in light of recommenda›
tions that emergency contraception be made available over
the counter.5 If patients are fully anticoagulated with war›
farin, the conventional Yuzpe regimen may be effective
without being associated with any increased risk of venous
thromboembolism.
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Barthel score, change in Barthel score, and survival time of patients in hospice with cancer
Sample 1
(n=93)
Sample 2
(n=104)
P value
(Mann›Whitney
U test)
Mean (range) Barthel score at
admission
66 (3›100) 58 (2›100) 0.056
Median (range) length of stay (days) 18 (5›104) 19 (3›86) 0.82
Median (range) survival (days) 35 (5›473) 27 (3›349) 0.2
Median (interquartile range) change in Barthel index:
No loss of points 56 (23›137) (n=50) 68 (19›128) (n=41) 0.91
1›9 points lost 32 (17›56) (n=24) 31 (15›45) (n=39) 0.51
>10 points lost 14 (11›20) (n=19) 15 (6›20) (n=24) 0.65
P value (Kruskal›Wallis test) <0.001 <0.001 –
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